Stockscreener 앱 받기
2.36
1.26%
-0.03
시장 영업 전:
2.44
0.08
+3.39%
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Risk vs reward if holding onto Kiora Pharmaceuticals Inc.Deep Stock Performance and Volatility Analysis - Newser
Kiora Pharmaceuticals Inc. stock momentum explainedHistorical Volatility and Pattern Breakdown Analysis - Newser
Building trade automation scripts for Kiora Pharmaceuticals Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Is Kiora Pharmaceuticals Inc. still worth holding after the dipFree Watchlist for Smart Swing Trading - Newser
Using AI based signals to follow Kiora Pharmaceuticals Inc.Free Weekly Potential Breakout Stock List - Newser
What data driven models say about Kiora Pharmaceuticals Inc.’s futureFree Entry Plan for Oversold Reversal Stocks - Newser
Market reaction to Kiora Pharmaceuticals Inc.’s recent newsSmart Safety Strategy With Real Data Analysis - Newser
Strategies to average down on Kiora Pharmaceuticals Inc.High Accuracy Trade Setup Identification - Newser
Promising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals - TipRanks
Can swing trading help recover from Kiora Pharmaceuticals Inc. lossesFree Weekly Hot Picks With Buy Confidence - Newser
Why Kiora Pharmaceuticals Inc. stock attracts strong analyst attentionMonthly Long-Term Market Recap and Summary - Newser
Kiora (KPRX) Q2 Revenue Falls 100% - AOL.com
Applying sector rotation models to Kiora Pharmaceuticals Inc.Free Breakout Confirmation With Entry Tracker - Newser
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
What machine learning models say about Kiora Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
Reversal indicators forming on Kiora Pharmaceuticals Inc. stockFree Day Trading Signals With High Precision - Newser
Abacus Global Management, Inc. shares rise 10.27% intraday after Kiora Pharmaceuticals reported positive Phase 2 clinical trial results for KIO-104. - AInvest
Kiora Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Statistical indicators supporting Kiora Pharmaceuticals Inc.’s strengthShort-Term Swing Opportunity Summary Sheet - Newser
Kiora pharma reports Q2 results, advances retinal disease trials - Investing.com
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
Is Kiora Pharmaceuticals Inc. showing signs of accumulationFree Stable Entry High Return Opportunities - Newser
What makes Kiora Pharmaceuticals Inc. stock price move sharplyReal Time Growth Signal with Smart Setup - Newser
Kiora Pharmaceuticals Inc. Stock Support and Resistance Levels You Should KnowRisk/Reward Optimization Entry Point Analysis - Newser
Kiora CEO to Reveal Latest Retinal Disease Therapeutic Developments at Major Ophthalmology Conference - Stock Titan
Applying chart zones and confluence areas to Kiora Pharmaceuticals Inc.Retirement Investment Outlook and Return Summary - Newser
What earnings revisions data tells us about Kiora Pharmaceuticals Inc.Entry Optimization Guide with Volume Analysis - Newser
Key metrics from Kiora Pharmaceuticals Inc.’s quarterly dataFree Capital Protection Trading Strategies - Newser
Applying big data sentiment scoring on Kiora Pharmaceuticals Inc.Long Hold Investment Strategy with Growth Focus - Newser
Kiora's KIO-104 receives US patent for expanded protection of inflammatory retinal diseases - Eyes On Eyecare
Visualizing Kiora Pharmaceuticals Inc. stock with heatmapsDaily Market Movers Screener with Filters - Newser
What are the latest earnings results for Kiora Pharmaceuticals Inc.Maximize gains with proven stock analysis - Jammu Links News
What catalysts could drive Kiora Pharmaceuticals Inc. stock higher in 2025Capitalize on momentum-driven investment opportunities - Jammu Links News
Intraday Charts Show Spike in Kiora Pharmaceuticals Inc. ActivityEarly Entry Picks Before News Breakout Reviewed - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):